Consensus estimates for Emergent BioSolutions indicate Q3 2026 revenue of $123.22 million and an adjusted EPS loss of $0.45, with the current $6.81 stock price trading significantly below the $11.00 analyst price target.
Investors are primarily focused on the potential erosion of NARCAN sales following a $191 million non-cash impairment charge and intensifying competition from new over-the-counter naloxone entrants.
The reporting period follows a significant corporate restructuring in August 2026 that eliminated nearly 100 roles to achieve $40 million in annualized cost savings.
The market remains cautious after management recently slashed full-year revenue guidance, citing volatility in the timing of U.S. government medical countermeasure deliveries.